BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27898751)

  • 1. [Investigating the predictive value of RMI and ROMA indices in patients with ovarian tumors of uncertain dignity].
    Krascsenits G; Balázs B; Dudnyikova A; Purcsi K; Orosz E; Pete I
    Magy Onkol; 2016 Nov; 60(4):320-327. PubMed ID: 27898751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discriminative value of CA-125, HE4, Risk of Malignancy Index II (RMI-II) and Risk of Malignancy Algorithm (ROMA) in the differential diagnosis of pelvic masses: conclusions from a referral Centre in Portugal.
    Melo Â; Veríssimo R; Farinha M; Martins NN; Martins FN
    J Obstet Gynaecol; 2018 Nov; 38(8):1140-1145. PubMed ID: 29884096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?
    Yanaranop M; Anakrat V; Siricharoenthai S; Nakrangsee S; Thinkhamrop B
    Gynecol Obstet Invest; 2017; 82(1):47-53. PubMed ID: 27197526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass.
    Al Musalhi K; Al Kindi M; Al Aisary F; Ramadhan F; Al Rawahi T; Al Hatali K; Mula-Abed WA
    Oman Med J; 2016 Sep; 31(5):336-44. PubMed ID: 27602187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women.
    Davenport C; Rai N; Sharma P; Deeks JJ; Berhane S; Mallett S; Saha P; Champaneria R; Bayliss SE; Snell KI; Sundar S
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD011964. PubMed ID: 35879201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Lycke M; Kristjansdottir B; Sundfeldt K
    Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RMI and ROMA are equally effective in discriminating between benign and malignant gynecological tumors: A prospective population-based study.
    Liest AL; Omran AS; Mikiver R; Rosenberg P; Uppugunduri S
    Acta Obstet Gynecol Scand; 2019 Jan; 98(1):24-33. PubMed ID: 30216407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Ovarian Malignancy Algorithm versus Risk Malignancy Index-I for Preoperative Assessment of Adnexal Masses: A Systematic Review and Meta-Analysis.
    Chacón E; Dasí J; Caballero C; Alcázar JL
    Gynecol Obstet Invest; 2019; 84(6):591-598. PubMed ID: 31311023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of cutoff values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia.
    Winarto H; Laihad BJ; Nuranna L
    Asian Pac J Cancer Prev; 2014; 15(5):1949-53. PubMed ID: 24716917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses.
    Anton C; Carvalho FM; Oliveira EI; Maciel GA; Baracat EC; Carvalho JP
    Clinics (Sao Paulo); 2012; 67(5):437-41. PubMed ID: 22666786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
    Van Gorp T; Veldman J; Van Calster B; Cadron I; Leunen K; Amant F; Timmerman D; Vergote I
    Eur J Cancer; 2012 Jul; 48(11):1649-56. PubMed ID: 22226481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ovarian tumor markers of presumed benign ovarian tumors].
    Lahlou N; Brun JL
    J Gynecol Obstet Biol Reprod (Paris); 2013 Dec; 42(8):752-9. PubMed ID: 24210243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review.
    Dochez V; Caillon H; Vaucel E; Dimet J; Winer N; Ducarme G
    J Ovarian Res; 2019 Mar; 12(1):28. PubMed ID: 30917847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.
    Karlsen MA; Høgdall EV; Christensen IJ; Borgfeldt C; Kalapotharakos G; Zdrazilova-Dubska L; Chovanec J; Lok CA; Stiekema A; Mutz-Dehbalaie I; Rosenthal AN; Moore EK; Schodin BA; Sumpaico WW; Sundfeldt K; Kristjansdottir B; Zapardiel I; Høgdall CK
    Gynecol Oncol; 2015 Sep; 138(3):640-6. PubMed ID: 26086566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Value of Malignancy Risk Indices for Ovarian Masses in Premenopausal and Postmenopausal Women.
    Ertas S; Vural F; Vural F; Tufekci EC; Ertas AC; Kose G; Aka N
    Asian Pac J Cancer Prev; 2016; 17(4):2177-83. PubMed ID: 27221915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.
    Moore RG; Jabre-Raughley M; Brown AK; Robison KM; Miller MC; Allard WJ; Kurman RJ; Bast RC; Skates SJ
    Am J Obstet Gynecol; 2010 Sep; 203(3):228.e1-6. PubMed ID: 20471625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass.
    Håkansson F; Høgdall EV; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Høgdall C;
    Acta Obstet Gynecol Scand; 2012 Apr; 91(4):496-502. PubMed ID: 22229703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive values of the ultrasound parameters, CA-125 and risk of malignancy index in patients with ovarian cancer.
    Antovska SV; Bashevska N; Aleksioska N
    Klin Onkol; 2011; 24(6):435-42. PubMed ID: 22257232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses.
    Morgante G; la Marca A; Ditto A; De Leo V
    Br J Obstet Gynaecol; 1999 Jun; 106(6):524-7. PubMed ID: 10426607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of malignancy index (RMI) in diagnosis of ovarian malignancy.
    Moolthiya W; Yuenyao P
    Asian Pac J Cancer Prev; 2009; 10(5):865-8. PubMed ID: 20162854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.